Cargando…
Feasibility Analysis of p62 (SQSTM1)—Encoding DNA Vaccine as a Novel Cancer Immunotherapy
Cancer immunotherapy is a thriving field, but its clinical achievements are modest so far. One of its major hurdles seems to be finding a feasible cancer antigen as a target for immune response. After many years of research, three major criteria for choice of tumor antigens emerged. An antigen shoul...
Autores principales: | Gabai, Vladimir L., Shifrin, Victor I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438419/ https://www.ncbi.nlm.nih.gov/pubmed/25277339 http://dx.doi.org/10.3109/08830185.2014.954699 |
Ejemplares similares
-
P62/SQSTM1 beyond Autophagy: Physiological Role and Therapeutic Applications in Laboratory and Domestic Animals
por: Sabbieti, Maria Giovanna, et al.
Publicado: (2022) -
Pilot study of p62 DNA vaccine in dogs with mammary tumors
por: Gabai, Vladimir, et al.
Publicado: (2014) -
Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector
por: Venanzi, Franco, et al.
Publicado: (2013) -
p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model
por: Kolosova, Nataliya G., et al.
Publicado: (2018) -
Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent
por: Sabbieti, Maria Giovanna, et al.
Publicado: (2015)